Mycophenolate mofetil in lupus glomerulonephritis

American Journal of Kidney Diseases

Volumn 40, Issue 3, 2002, Pages 447-457

  Mok, Chi Chiu ^a   Lai, Kar Neng ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Cyclophosphamide (CYC); Cytotoxic; Immunosuppressive; Lupus nephritis; Proliferative; Renal

Indexed keywords

AZATHIOPRINE; CELL ADHESION MOLECULE; CORTICOSTEROID; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA; DNA POLYMERASE; DOUBLE STRANDED DNA; FLUDARABINE; GAMMA INTERFERON; GLUCURONIDE; GLYCOPROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INOSINATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 2; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; SERUM ALBUMIN; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AMENORRHEA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GONADAL DISEASE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; OVARY DISEASE; PANCYTOPENIA; PROTEINURIA; REVIEW;

EID: 0036724303     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.34882     Document Type: Article

References (72)

1. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus
2. A comparison of the quality of life of patients with systemic lupus erythematosus with and without end stage renal disease
3. Lupus nephritis in southern Chinese patients: Clinicopathological findings and long-term outcome
4. The course and treatment of lupus nephritis
5. The prognosis of lupus nephritis in African-Americans: A retrospective analysis
6. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
7. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
8. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
9. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine
10. Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens
11. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study
12. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial
13. Controlled trial of pulse methylprednisolone versus two regimens of pulse CYC in severe lupus nephritis
14. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis
15. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: Efficacy in steroid unresponsive lupus nephritis
16. Infection in systemic lupus erythematosus
17. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death
18. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
19. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy
20. Progress in the treatment of proliferative lupus nephritis
21. Advances in the treatment of lupus nephritis
22. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
23. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
24. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
25. Non-transplant uses of mycophenolate mofetil
26. Mycophenolate mofetil in lupus nephritis
27. Cytomegalovirus colitis during mycophenolate mofetil therapy for Wegener's granulomatosis
28. Treatment of systemic lupus erythematosus with mycophenolate mofetil
29. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases
30. Mycophenolic acid for psoriasis: A review of pharmacology, long term efficacy and safety
31. Mycophenolate mofetil and its mechanisms of action
32. Characterization of human type I and type II IMP dehydrogenases
33. Lymphocyteselective antiproliferative and immunosuppressive effects of mycophenolic acid in mice
34. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion
35. Effects of combined administration of FK506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures
36. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443
37. Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro
38. Effect of mycophenolate mofetil (RS-61443) on cytokine production: Inhibition of superantigen-induced cytokines
39. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines
40. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells
41. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates
42. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion
43. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis
44. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease
45. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus
46. Mycophenolate mofetil combined with a cyclooxygenase- 2 inhibitor ameliorates murine lupus nephritis
47. Attenuation of murine lupus nephritis by mycophenolate mofetil
48. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRL1pr/1pr mice
49. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRL1pr/1pr mice
50. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/1pr mice
51. Successful mycophenolate mofetil treatment of glomerular disease
52. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide
53. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: An open pilot trial
54. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
55. The safety and efficacy of MMF in lupus nephritis: A pilot study
56. Late recurrence of lupus nephritis in a renal transplant recipient: Response to mycophenolate mofetil
57. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine
58. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus
59. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
60. Prolonged follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil
61. Comparison of mycophenolate mofetil versus cyclophosphamide pulse therapy in the induction treatment of severe diffuse proliferative lupus nephritis in Chinese population
62. Mycophenolate mofetil versus cyclophosphamide in the treatment of severe systemic lupus erythematosus patients
63. Immunosuppressive therapy for proliferative lupus nephritis: Preliminary report of a prospective randomized clinical trial with mycophenolate mofetil
64. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis
65. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
66. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil
67. Chilblain lupus erythematosus Hutchinson: Successful treatment with mycophenolate mofetil
68. Mycophenolate mofetil: A new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection
69. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
70. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
71. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation